nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ALB—coronary artery disease	0.0404	1	CbGaD
Erlotinib—SLCO2B1—Pitavastatin—coronary artery disease	0.0322	0.0533	CbGbCtD
Erlotinib—SLCO2B1—Niacin—coronary artery disease	0.0279	0.0462	CbGbCtD
Erlotinib—ORM1—Penbutolol—coronary artery disease	0.0248	0.041	CbGbCtD
Erlotinib—SLCO2B1—Rosuvastatin—coronary artery disease	0.0237	0.0393	CbGbCtD
Erlotinib—ORM1—Pitavastatin—coronary artery disease	0.0217	0.0359	CbGbCtD
Erlotinib—SLCO2B1—Pravastatin—coronary artery disease	0.0216	0.0357	CbGbCtD
Erlotinib—SLCO2B1—Atorvastatin—coronary artery disease	0.0197	0.0325	CbGbCtD
Erlotinib—UGT1A1—Ezetimibe—coronary artery disease	0.0177	0.0293	CbGbCtD
Erlotinib—UGT1A1—Simvastatin—coronary artery disease	0.0165	0.0273	CbGbCtD
Erlotinib—UGT1A1—Lovastatin—coronary artery disease	0.0161	0.0267	CbGbCtD
Erlotinib—UGT1A1—Atorvastatin—coronary artery disease	0.0147	0.0243	CbGbCtD
Erlotinib—UGT1A1—Losartan—coronary artery disease	0.0134	0.0222	CbGbCtD
Erlotinib—ABCG2—Pitavastatin—coronary artery disease	0.0132	0.0219	CbGbCtD
Erlotinib—ABCG2—Telmisartan—coronary artery disease	0.0132	0.0219	CbGbCtD
Erlotinib—CYP2C8—Fenofibrate—coronary artery disease	0.0116	0.0192	CbGbCtD
Erlotinib—ABCG2—Rosuvastatin—coronary artery disease	0.00975	0.0161	CbGbCtD
Erlotinib—ABCG2—Ezetimibe—coronary artery disease	0.00975	0.0161	CbGbCtD
Erlotinib—CYP2C8—Gemfibrozil—coronary artery disease	0.00929	0.0154	CbGbCtD
Erlotinib—ALB—Pitavastatin—coronary artery disease	0.00911	0.0151	CbGbCtD
Erlotinib—ABCG2—Pravastatin—coronary artery disease	0.00887	0.0147	CbGbCtD
Erlotinib—ALB—Valsartan—coronary artery disease	0.00886	0.0147	CbGbCtD
Erlotinib—ABCB1—Ticagrelor—coronary artery disease	0.00883	0.0146	CbGbCtD
Erlotinib—CYP3A5—Clopidogrel—coronary artery disease	0.00838	0.0139	CbGbCtD
Erlotinib—CYP2C8—Clopidogrel—coronary artery disease	0.00806	0.0133	CbGbCtD
Erlotinib—CYP3A5—Eplerenone—coronary artery disease	0.00779	0.0129	CbGbCtD
Erlotinib—CYP1A2—Gemfibrozil—coronary artery disease	0.00719	0.0119	CbGbCtD
Erlotinib—CYP2C8—Pitavastatin—coronary artery disease	0.00704	0.0117	CbGbCtD
Erlotinib—ALB—Rosuvastatin—coronary artery disease	0.00672	0.0111	CbGbCtD
Erlotinib—ALB—Acetylsalicylic acid—coronary artery disease	0.00655	0.0108	CbGbCtD
Erlotinib—ALB—Captopril—coronary artery disease	0.00647	0.0107	CbGbCtD
Erlotinib—CYP1A2—Clopidogrel—coronary artery disease	0.00624	0.0103	CbGbCtD
Erlotinib—ABCB1—Clopidogrel—coronary artery disease	0.00545	0.00903	CbGbCtD
Erlotinib—ABCB1—Perindopril—coronary artery disease	0.00545	0.00903	CbGbCtD
Erlotinib—CYP3A5—Rosuvastatin—coronary artery disease	0.0054	0.00894	CbGbCtD
Erlotinib—CYP3A4—Ticagrelor—coronary artery disease	0.00529	0.00875	CbGbCtD
Erlotinib—ALB—Furosemide—coronary artery disease	0.0052	0.0086	CbGbCtD
Erlotinib—ALB—Losartan—coronary artery disease	0.00509	0.00843	CbGbCtD
Erlotinib—CYP2C8—Acetylsalicylic acid—coronary artery disease	0.00506	0.00837	CbGbCtD
Erlotinib—CYP3A5—Simvastatin—coronary artery disease	0.00502	0.00831	CbGbCtD
Erlotinib—CYP3A5—Lovastatin—coronary artery disease	0.00491	0.00813	CbGbCtD
Erlotinib—CYP3A5—Pravastatin—coronary artery disease	0.00491	0.00813	CbGbCtD
Erlotinib—CYP2C8—Simvastatin—coronary artery disease	0.00483	0.00799	CbGbCtD
Erlotinib—ABCB1—Pitavastatin—coronary artery disease	0.00477	0.00789	CbGbCtD
Erlotinib—ABCB1—Telmisartan—coronary artery disease	0.00477	0.00789	CbGbCtD
Erlotinib—CYP2C8—Lovastatin—coronary artery disease	0.00472	0.00782	CbGbCtD
Erlotinib—CYP2C8—Pravastatin—coronary artery disease	0.00472	0.00782	CbGbCtD
Erlotinib—CYP3A4—Fenofibrate—coronary artery disease	0.00471	0.0078	CbGbCtD
Erlotinib—ABCB1—Lisinopril—coronary artery disease	0.00452	0.00748	CbGbCtD
Erlotinib—ABCB1—Enalapril—coronary artery disease	0.00452	0.00748	CbGbCtD
Erlotinib—CYP3A5—Atorvastatin—coronary artery disease	0.00447	0.00741	CbGbCtD
Erlotinib—CYP2C8—Atorvastatin—coronary artery disease	0.0043	0.00712	CbGbCtD
Erlotinib—CYP3A5—Losartan—coronary artery disease	0.00409	0.00677	CbGbCtD
Erlotinib—CYP2C8—Losartan—coronary artery disease	0.00393	0.00651	CbGbCtD
Erlotinib—CYP2D6—Niacin—coronary artery disease	0.00389	0.00645	CbGbCtD
Erlotinib—ABCB1—Timolol—coronary artery disease	0.00384	0.00636	CbGbCtD
Erlotinib—CYP3A4—Gemfibrozil—coronary artery disease	0.00377	0.00624	CbGbCtD
Erlotinib—CYP2D6—Timolol—coronary artery disease	0.00362	0.00599	CbGbCtD
Erlotinib—ABCB1—Ezetimibe—coronary artery disease	0.00351	0.00582	CbGbCtD
Erlotinib—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00342	0.00567	CbGbCtD
Erlotinib—ABCB1—Captopril—coronary artery disease	0.00338	0.0056	CbGbCtD
Erlotinib—CYP3A4—Clopidogrel—coronary artery disease	0.00327	0.00541	CbGbCtD
Erlotinib—ABCB1—Simvastatin—coronary artery disease	0.00327	0.00541	CbGbCtD
Erlotinib—ABCB1—Pravastatin—coronary artery disease	0.0032	0.00529	CbGbCtD
Erlotinib—ABCB1—Lovastatin—coronary artery disease	0.0032	0.00529	CbGbCtD
Erlotinib—CYP2D6—Captopril—coronary artery disease	0.00319	0.00528	CbGbCtD
Erlotinib—CYP2D6—Simvastatin—coronary artery disease	0.00308	0.0051	CbGbCtD
Erlotinib—CYP1A2—Losartan—coronary artery disease	0.00305	0.00504	CbGbCtD
Erlotinib—CYP3A4—Eplerenone—coronary artery disease	0.00304	0.00503	CbGbCtD
Erlotinib—CYP2D6—Pravastatin—coronary artery disease	0.00301	0.00499	CbGbCtD
Erlotinib—CYP2D6—Lovastatin—coronary artery disease	0.00301	0.00499	CbGbCtD
Erlotinib—ABCB1—Atorvastatin—coronary artery disease	0.00291	0.00482	CbGbCtD
Erlotinib—CYP2D6—Atorvastatin—coronary artery disease	0.00274	0.00454	CbGbCtD
Erlotinib—CYP3A4—Enalapril—coronary artery disease	0.00271	0.00448	CbGbCtD
Erlotinib—ABCB1—Losartan—coronary artery disease	0.00266	0.00441	CbGbCtD
Erlotinib—CYP3A4—Rosuvastatin—coronary artery disease	0.00211	0.00349	CbGbCtD
Erlotinib—CYP3A4—Ezetimibe—coronary artery disease	0.00211	0.00349	CbGbCtD
Erlotinib—CYP3A4—Simvastatin—coronary artery disease	0.00196	0.00324	CbGbCtD
Erlotinib—CYP3A4—Lovastatin—coronary artery disease	0.00192	0.00317	CbGbCtD
Erlotinib—CYP3A4—Pravastatin—coronary artery disease	0.00192	0.00317	CbGbCtD
Erlotinib—CYP3A4—Atorvastatin—coronary artery disease	0.00174	0.00289	CbGbCtD
Erlotinib—CYP3A4—Losartan—coronary artery disease	0.0016	0.00264	CbGbCtD
Erlotinib—Vandetanib—TEK—coronary artery disease	0.0013	0.433	CrCbGaD
Erlotinib—AURKC—heart—coronary artery disease	0.00116	0.0323	CbGeAlD
Erlotinib—ULK3—cardiac ventricle—coronary artery disease	0.00111	0.031	CbGeAlD
Erlotinib—PIP4K2C—myocardium—coronary artery disease	0.0011	0.0305	CbGeAlD
Erlotinib—JAK3—heart—coronary artery disease	0.00108	0.0299	CbGeAlD
Erlotinib—MKNK1—cardiac ventricle—coronary artery disease	0.00105	0.0292	CbGeAlD
Erlotinib—ULK3—myocardium—coronary artery disease	0.00105	0.0292	CbGeAlD
Erlotinib—SLK—cardiac ventricle—coronary artery disease	0.000994	0.0276	CbGeAlD
Erlotinib—TNK1—heart—coronary artery disease	0.000988	0.0275	CbGeAlD
Erlotinib—MKNK1—myocardium—coronary artery disease	0.000987	0.0274	CbGeAlD
Erlotinib—SLK—myocardium—coronary artery disease	0.000935	0.026	CbGeAlD
Erlotinib—FLT3—heart—coronary artery disease	0.000849	0.0236	CbGeAlD
Erlotinib—ABL2—heart—coronary artery disease	0.00081	0.0225	CbGeAlD
Erlotinib—JAK3—blood—coronary artery disease	0.000803	0.0223	CbGeAlD
Erlotinib—FLT3—cardiovascular system—coronary artery disease	0.000801	0.0223	CbGeAlD
Erlotinib—EGFR—heart—coronary artery disease	0.000791	0.022	CbGeAlD
Erlotinib—PIP4K2C—heart—coronary artery disease	0.000767	0.0213	CbGeAlD
Erlotinib—TNK1—blood—coronary artery disease	0.000737	0.0205	CbGeAlD
Erlotinib—ULK3—heart—coronary artery disease	0.000732	0.0203	CbGeAlD
Erlotinib—MAP2K5—myocardium—coronary artery disease	0.000726	0.0202	CbGeAlD
Erlotinib—MKNK1—heart—coronary artery disease	0.000689	0.0192	CbGeAlD
Erlotinib—PIP4K2C—cardiac atrium—coronary artery disease	0.000656	0.0182	CbGeAlD
Erlotinib—SLK—heart—coronary artery disease	0.000652	0.0181	CbGeAlD
Erlotinib—MKNK1—cardiovascular system—coronary artery disease	0.00065	0.0181	CbGeAlD
Erlotinib—Vandetanib—KDR—coronary artery disease	0.000637	0.211	CrCbGaD
Erlotinib—FLT3—blood—coronary artery disease	0.000633	0.0176	CbGeAlD
Erlotinib—ULK3—cardiac atrium—coronary artery disease	0.000626	0.0174	CbGeAlD
Erlotinib—ABL2—blood—coronary artery disease	0.000605	0.0168	CbGeAlD
Erlotinib—ABL1—cardiac ventricle—coronary artery disease	0.000595	0.0165	CbGeAlD
Erlotinib—MKNK1—cardiac atrium—coronary artery disease	0.000589	0.0164	CbGeAlD
Erlotinib—PIP4K2C—blood—coronary artery disease	0.000572	0.0159	CbGeAlD
Erlotinib—STK10—heart—coronary artery disease	0.000567	0.0158	CbGeAlD
Erlotinib—ABL1—myocardium—coronary artery disease	0.00056	0.0156	CbGeAlD
Erlotinib—SLK—cardiac atrium—coronary artery disease	0.000558	0.0155	CbGeAlD
Erlotinib—ULK3—blood—coronary artery disease	0.000546	0.0152	CbGeAlD
Erlotinib—Vandetanib—VEGFA—coronary artery disease	0.00054	0.179	CrCbGaD
Erlotinib—STK10—cardiovascular system—coronary artery disease	0.000535	0.0149	CbGeAlD
Erlotinib—MKNK1—blood—coronary artery disease	0.000514	0.0143	CbGeAlD
Erlotinib—MAP2K5—heart—coronary artery disease	0.000507	0.0141	CbGeAlD
Erlotinib—SLK—blood—coronary artery disease	0.000487	0.0135	CbGeAlD
Erlotinib—MAP2K5—cardiovascular system—coronary artery disease	0.000478	0.0133	CbGeAlD
Erlotinib—MAP2K5—cardiac atrium—coronary artery disease	0.000433	0.012	CbGeAlD
Erlotinib—STK10—blood—coronary artery disease	0.000423	0.0118	CbGeAlD
Erlotinib—UGT1A1—blood—coronary artery disease	0.0004	0.0111	CbGeAlD
Erlotinib—SLCO2B1—heart—coronary artery disease	0.000394	0.011	CbGeAlD
Erlotinib—ABL1—heart—coronary artery disease	0.000391	0.0109	CbGeAlD
Erlotinib—MAP2K5—blood—coronary artery disease	0.000378	0.0105	CbGeAlD
Erlotinib—ABL1—cardiovascular system—coronary artery disease	0.000369	0.0103	CbGeAlD
Erlotinib—ALB—heart—coronary artery disease	0.000361	0.01	CbGeAlD
Erlotinib—CYP1A1—cardiac ventricle—coronary artery disease	0.000356	0.00991	CbGeAlD
Erlotinib—ABL1—cardiac atrium—coronary artery disease	0.000334	0.00929	CbGeAlD
Erlotinib—CYP1B1—heart—coronary artery disease	0.000331	0.0092	CbGeAlD
Erlotinib—CYP1B1—cardiovascular system—coronary artery disease	0.000312	0.00868	CbGeAlD
Erlotinib—ORM1—blood—coronary artery disease	0.000307	0.00853	CbGeAlD
Erlotinib—ABL1—blood—coronary artery disease	0.000292	0.00811	CbGeAlD
Erlotinib—Gefitinib—CYP2C19—coronary artery disease	0.000249	0.0825	CrCbGaD
Erlotinib—CYP1B1—blood—coronary artery disease	0.000247	0.00687	CbGeAlD
Erlotinib—ABCG2—heart—coronary artery disease	0.000246	0.00685	CbGeAlD
Erlotinib—CYP1A1—heart—coronary artery disease	0.000234	0.0065	CbGeAlD
Erlotinib—CYP1A1—cardiac atrium—coronary artery disease	0.0002	0.00556	CbGeAlD
Erlotinib—CYP2C8—blood—coronary artery disease	0.000189	0.00526	CbGeAlD
Erlotinib—ABCG2—blood—coronary artery disease	0.000184	0.00511	CbGeAlD
Erlotinib—CYP1A2—blood—coronary artery disease	0.000177	0.00492	CbGeAlD
Erlotinib—CYP1A1—blood—coronary artery disease	0.000175	0.00485	CbGeAlD
Erlotinib—CYP3A5—blood—coronary artery disease	0.000171	0.00475	CbGeAlD
Erlotinib—Vandetanib—ALB—coronary artery disease	0.000145	0.0482	CrCbGaD
Erlotinib—Gefitinib—ALB—coronary artery disease	0.000138	0.0458	CrCbGaD
Erlotinib—CYP3A4—blood—coronary artery disease	0.000128	0.00356	CbGeAlD
Erlotinib—CYP2D6—blood—coronary artery disease	0.000126	0.00351	CbGeAlD
Erlotinib—ABCB1—heart—coronary artery disease	0.000122	0.00338	CbGeAlD
Erlotinib—ABCB1—cardiovascular system—coronary artery disease	0.000115	0.00319	CbGeAlD
Erlotinib—ABCB1—blood—coronary artery disease	9.07e-05	0.00252	CbGeAlD
Erlotinib—Gastrointestinal pain—Captopril—coronary artery disease	6.26e-05	0.000348	CcSEcCtD
Erlotinib—Cough—Timolol—coronary artery disease	6.25e-05	0.000347	CcSEcCtD
Erlotinib—Vomiting—Clopidogrel—coronary artery disease	6.24e-05	0.000347	CcSEcCtD
Erlotinib—Diarrhoea—Simvastatin—coronary artery disease	6.24e-05	0.000347	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Furosemide—coronary artery disease	6.24e-05	0.000347	CcSEcCtD
Erlotinib—Chest pain—Ramipril—coronary artery disease	6.23e-05	0.000346	CcSEcCtD
Erlotinib—Myalgia—Ramipril—coronary artery disease	6.23e-05	0.000346	CcSEcCtD
Erlotinib—Arthralgia—Ramipril—coronary artery disease	6.23e-05	0.000346	CcSEcCtD
Erlotinib—Fatigue—Furosemide—coronary artery disease	6.23e-05	0.000346	CcSEcCtD
Erlotinib—Body temperature increased—Telmisartan—coronary artery disease	6.22e-05	0.000346	CcSEcCtD
Erlotinib—Abdominal pain—Telmisartan—coronary artery disease	6.22e-05	0.000346	CcSEcCtD
Erlotinib—Dyspnoea—Losartan—coronary artery disease	6.21e-05	0.000345	CcSEcCtD
Erlotinib—Anxiety—Ramipril—coronary artery disease	6.21e-05	0.000345	CcSEcCtD
Erlotinib—Vomiting—Lovastatin—coronary artery disease	6.2e-05	0.000345	CcSEcCtD
Erlotinib—Dizziness—Eplerenone—coronary artery disease	6.19e-05	0.000344	CcSEcCtD
Erlotinib—Rash—Clopidogrel—coronary artery disease	6.19e-05	0.000344	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	6.19e-05	0.000344	CcSEcCtD
Erlotinib—Dermatitis—Clopidogrel—coronary artery disease	6.19e-05	0.000344	CcSEcCtD
Erlotinib—Asthenia—Valsartan—coronary artery disease	6.18e-05	0.000344	CcSEcCtD
Erlotinib—Constipation—Furosemide—coronary artery disease	6.18e-05	0.000343	CcSEcCtD
Erlotinib—Pain—Furosemide—coronary artery disease	6.18e-05	0.000343	CcSEcCtD
Erlotinib—Asthenia—Olmesartan—coronary artery disease	6.15e-05	0.000342	CcSEcCtD
Erlotinib—Headache—Clopidogrel—coronary artery disease	6.15e-05	0.000342	CcSEcCtD
Erlotinib—Rash—Lovastatin—coronary artery disease	6.15e-05	0.000342	CcSEcCtD
Erlotinib—Dermatitis—Lovastatin—coronary artery disease	6.14e-05	0.000342	CcSEcCtD
Erlotinib—Dyspepsia—Losartan—coronary artery disease	6.13e-05	0.000341	CcSEcCtD
Erlotinib—Headache—Lovastatin—coronary artery disease	6.11e-05	0.00034	CcSEcCtD
Erlotinib—Pruritus—Valsartan—coronary artery disease	6.1e-05	0.000339	CcSEcCtD
Erlotinib—Chest pain—Timolol—coronary artery disease	6.09e-05	0.000339	CcSEcCtD
Erlotinib—Myalgia—Timolol—coronary artery disease	6.09e-05	0.000339	CcSEcCtD
Erlotinib—Arthralgia—Timolol—coronary artery disease	6.09e-05	0.000339	CcSEcCtD
Erlotinib—Vomiting—Ezetimibe—coronary artery disease	6.08e-05	0.000338	CcSEcCtD
Erlotinib—Gastrointestinal pain—Perindopril—coronary artery disease	6.08e-05	0.000338	CcSEcCtD
Erlotinib—Anxiety—Timolol—coronary artery disease	6.07e-05	0.000338	CcSEcCtD
Erlotinib—Pruritus—Olmesartan—coronary artery disease	6.07e-05	0.000337	CcSEcCtD
Erlotinib—Decreased appetite—Losartan—coronary artery disease	6.06e-05	0.000337	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	6.05e-05	0.000336	CcSEcCtD
Erlotinib—Body temperature increased—Captopril—coronary artery disease	6.05e-05	0.000336	CcSEcCtD
Erlotinib—Abdominal pain—Captopril—coronary artery disease	6.05e-05	0.000336	CcSEcCtD
Erlotinib—Dizziness—Simvastatin—coronary artery disease	6.03e-05	0.000335	CcSEcCtD
Erlotinib—Rash—Ezetimibe—coronary artery disease	6.03e-05	0.000335	CcSEcCtD
Erlotinib—Dermatitis—Ezetimibe—coronary artery disease	6.03e-05	0.000335	CcSEcCtD
Erlotinib—Asthenia—Niacin—coronary artery disease	6.01e-05	0.000334	CcSEcCtD
Erlotinib—Fatigue—Losartan—coronary artery disease	6.01e-05	0.000334	CcSEcCtD
Erlotinib—Headache—Ezetimibe—coronary artery disease	5.99e-05	0.000333	CcSEcCtD
Erlotinib—Oedema—Ramipril—coronary artery disease	5.98e-05	0.000332	CcSEcCtD
Erlotinib—Pain—Losartan—coronary artery disease	5.96e-05	0.000331	CcSEcCtD
Erlotinib—Constipation—Losartan—coronary artery disease	5.96e-05	0.000331	CcSEcCtD
Erlotinib—Syncope—Lisinopril—coronary artery disease	5.95e-05	0.000331	CcSEcCtD
Erlotinib—Vomiting—Eplerenone—coronary artery disease	5.95e-05	0.000331	CcSEcCtD
Erlotinib—Nausea—Fenofibrate—coronary artery disease	5.93e-05	0.00033	CcSEcCtD
Erlotinib—Pruritus—Niacin—coronary artery disease	5.93e-05	0.000329	CcSEcCtD
Erlotinib—Asthenia—Pravastatin—coronary artery disease	5.92e-05	0.000329	CcSEcCtD
Erlotinib—Gastrointestinal pain—Furosemide—coronary artery disease	5.91e-05	0.000328	CcSEcCtD
Erlotinib—Rash—Eplerenone—coronary artery disease	5.9e-05	0.000328	CcSEcCtD
Erlotinib—Dermatitis—Eplerenone—coronary artery disease	5.9e-05	0.000328	CcSEcCtD
Erlotinib—Diarrhoea—Valsartan—coronary artery disease	5.9e-05	0.000328	CcSEcCtD
Erlotinib—Shock—Ramipril—coronary artery disease	5.88e-05	0.000327	CcSEcCtD
Erlotinib—Abdominal pain—Perindopril—coronary artery disease	5.87e-05	0.000326	CcSEcCtD
Erlotinib—Body temperature increased—Perindopril—coronary artery disease	5.87e-05	0.000326	CcSEcCtD
Erlotinib—Diarrhoea—Olmesartan—coronary artery disease	5.87e-05	0.000326	CcSEcCtD
Erlotinib—Headache—Eplerenone—coronary artery disease	5.87e-05	0.000326	CcSEcCtD
Erlotinib—Nervous system disorder—Ramipril—coronary artery disease	5.86e-05	0.000326	CcSEcCtD
Erlotinib—Thrombocytopenia—Ramipril—coronary artery disease	5.85e-05	0.000325	CcSEcCtD
Erlotinib—Oedema—Timolol—coronary artery disease	5.84e-05	0.000325	CcSEcCtD
Erlotinib—Pruritus—Pravastatin—coronary artery disease	5.84e-05	0.000324	CcSEcCtD
Erlotinib—Loss of consciousness—Lisinopril—coronary artery disease	5.84e-05	0.000324	CcSEcCtD
Erlotinib—Nausea—Clopidogrel—coronary artery disease	5.83e-05	0.000324	CcSEcCtD
Erlotinib—Skin disorder—Ramipril—coronary artery disease	5.8e-05	0.000323	CcSEcCtD
Erlotinib—Infection—Timolol—coronary artery disease	5.8e-05	0.000323	CcSEcCtD
Erlotinib—Vomiting—Simvastatin—coronary artery disease	5.8e-05	0.000322	CcSEcCtD
Erlotinib—Cough—Lisinopril—coronary artery disease	5.79e-05	0.000322	CcSEcCtD
Erlotinib—Nausea—Lovastatin—coronary artery disease	5.79e-05	0.000322	CcSEcCtD
Erlotinib—Rash—Simvastatin—coronary artery disease	5.75e-05	0.00032	CcSEcCtD
Erlotinib—Dermatitis—Simvastatin—coronary artery disease	5.75e-05	0.000319	CcSEcCtD
Erlotinib—Asthenia—Trandolapril—coronary artery disease	5.75e-05	0.000319	CcSEcCtD
Erlotinib—Shock—Timolol—coronary artery disease	5.75e-05	0.000319	CcSEcCtD
Erlotinib—Diarrhoea—Niacin—coronary artery disease	5.73e-05	0.000319	CcSEcCtD
Erlotinib—Nervous system disorder—Timolol—coronary artery disease	5.73e-05	0.000318	CcSEcCtD
Erlotinib—Asthenia—Enalapril—coronary artery disease	5.72e-05	0.000318	CcSEcCtD
Erlotinib—Headache—Simvastatin—coronary artery disease	5.72e-05	0.000318	CcSEcCtD
Erlotinib—Abdominal pain—Furosemide—coronary artery disease	5.71e-05	0.000317	CcSEcCtD
Erlotinib—Body temperature increased—Furosemide—coronary artery disease	5.71e-05	0.000317	CcSEcCtD
Erlotinib—Gastrointestinal pain—Losartan—coronary artery disease	5.7e-05	0.000317	CcSEcCtD
Erlotinib—Dizziness—Valsartan—coronary artery disease	5.7e-05	0.000317	CcSEcCtD
Erlotinib—Anorexia—Ramipril—coronary artery disease	5.7e-05	0.000317	CcSEcCtD
Erlotinib—Nausea—Ezetimibe—coronary artery disease	5.68e-05	0.000316	CcSEcCtD
Erlotinib—Skin disorder—Timolol—coronary artery disease	5.67e-05	0.000315	CcSEcCtD
Erlotinib—Dizziness—Olmesartan—coronary artery disease	5.67e-05	0.000315	CcSEcCtD
Erlotinib—Pruritus—Trandolapril—coronary artery disease	5.67e-05	0.000315	CcSEcCtD
Erlotinib—Chest pain—Lisinopril—coronary artery disease	5.65e-05	0.000314	CcSEcCtD
Erlotinib—Arthralgia—Lisinopril—coronary artery disease	5.65e-05	0.000314	CcSEcCtD
Erlotinib—Myalgia—Lisinopril—coronary artery disease	5.65e-05	0.000314	CcSEcCtD
Erlotinib—Asthenia—Telmisartan—coronary artery disease	5.65e-05	0.000314	CcSEcCtD
Erlotinib—Pruritus—Enalapril—coronary artery disease	5.64e-05	0.000314	CcSEcCtD
Erlotinib—Diarrhoea—Pravastatin—coronary artery disease	5.64e-05	0.000314	CcSEcCtD
Erlotinib—Anxiety—Lisinopril—coronary artery disease	5.63e-05	0.000313	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	5.61e-05	0.000312	CcSEcCtD
Erlotinib—Anorexia—Timolol—coronary artery disease	5.57e-05	0.00031	CcSEcCtD
Erlotinib—Pruritus—Telmisartan—coronary artery disease	5.57e-05	0.000309	CcSEcCtD
Erlotinib—Nausea—Eplerenone—coronary artery disease	5.56e-05	0.000309	CcSEcCtD
Erlotinib—Dizziness—Niacin—coronary artery disease	5.54e-05	0.000308	CcSEcCtD
Erlotinib—Abdominal pain—Losartan—coronary artery disease	5.51e-05	0.000306	CcSEcCtD
Erlotinib—Body temperature increased—Losartan—coronary artery disease	5.51e-05	0.000306	CcSEcCtD
Erlotinib—Asthenia—Captopril—coronary artery disease	5.49e-05	0.000305	CcSEcCtD
Erlotinib—Diarrhoea—Trandolapril—coronary artery disease	5.48e-05	0.000305	CcSEcCtD
Erlotinib—Vomiting—Valsartan—coronary artery disease	5.48e-05	0.000305	CcSEcCtD
Erlotinib—Diarrhoea—Enalapril—coronary artery disease	5.46e-05	0.000303	CcSEcCtD
Erlotinib—Dizziness—Pravastatin—coronary artery disease	5.45e-05	0.000303	CcSEcCtD
Erlotinib—Vomiting—Olmesartan—coronary artery disease	5.45e-05	0.000303	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Ramipril—coronary artery disease	5.44e-05	0.000303	CcSEcCtD
Erlotinib—Rash—Valsartan—coronary artery disease	5.43e-05	0.000302	CcSEcCtD
Erlotinib—Dermatitis—Valsartan—coronary artery disease	5.43e-05	0.000302	CcSEcCtD
Erlotinib—Nausea—Simvastatin—coronary artery disease	5.42e-05	0.000301	CcSEcCtD
Erlotinib—Oedema—Lisinopril—coronary artery disease	5.42e-05	0.000301	CcSEcCtD
Erlotinib—Pruritus—Captopril—coronary artery disease	5.41e-05	0.000301	CcSEcCtD
Erlotinib—Rash—Olmesartan—coronary artery disease	5.41e-05	0.000301	CcSEcCtD
Erlotinib—Insomnia—Ramipril—coronary artery disease	5.4e-05	0.0003	CcSEcCtD
Erlotinib—Dermatitis—Olmesartan—coronary artery disease	5.4e-05	0.0003	CcSEcCtD
Erlotinib—Headache—Valsartan—coronary artery disease	5.4e-05	0.0003	CcSEcCtD
Erlotinib—Diarrhoea—Telmisartan—coronary artery disease	5.38e-05	0.000299	CcSEcCtD
Erlotinib—Infection—Lisinopril—coronary artery disease	5.38e-05	0.000299	CcSEcCtD
Erlotinib—Headache—Olmesartan—coronary artery disease	5.37e-05	0.000299	CcSEcCtD
Erlotinib—Shock—Lisinopril—coronary artery disease	5.33e-05	0.000296	CcSEcCtD
Erlotinib—Asthenia—Perindopril—coronary artery disease	5.33e-05	0.000296	CcSEcCtD
Erlotinib—Dyspnoea—Ramipril—coronary artery disease	5.33e-05	0.000296	CcSEcCtD
Erlotinib—Vomiting—Niacin—coronary artery disease	5.33e-05	0.000296	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Timolol—coronary artery disease	5.32e-05	0.000296	CcSEcCtD
Erlotinib—Thrombocytopenia—Lisinopril—coronary artery disease	5.31e-05	0.000295	CcSEcCtD
Erlotinib—Dizziness—Trandolapril—coronary artery disease	5.3e-05	0.000294	CcSEcCtD
Erlotinib—Insomnia—Timolol—coronary artery disease	5.28e-05	0.000294	CcSEcCtD
Erlotinib—Rash—Niacin—coronary artery disease	5.28e-05	0.000294	CcSEcCtD
Erlotinib—Dermatitis—Niacin—coronary artery disease	5.28e-05	0.000293	CcSEcCtD
Erlotinib—Dizziness—Enalapril—coronary artery disease	5.28e-05	0.000293	CcSEcCtD
Erlotinib—Skin disorder—Lisinopril—coronary artery disease	5.26e-05	0.000293	CcSEcCtD
Erlotinib—Dyspepsia—Ramipril—coronary artery disease	5.26e-05	0.000292	CcSEcCtD
Erlotinib—Pruritus—Perindopril—coronary artery disease	5.26e-05	0.000292	CcSEcCtD
Erlotinib—Headache—Niacin—coronary artery disease	5.25e-05	0.000292	CcSEcCtD
Erlotinib—Vomiting—Pravastatin—coronary artery disease	5.24e-05	0.000292	CcSEcCtD
Erlotinib—Diarrhoea—Captopril—coronary artery disease	5.24e-05	0.000291	CcSEcCtD
Erlotinib—Dyspnoea—Timolol—coronary artery disease	5.21e-05	0.000289	CcSEcCtD
Erlotinib—Dizziness—Telmisartan—coronary artery disease	5.2e-05	0.000289	CcSEcCtD
Erlotinib—Rash—Pravastatin—coronary artery disease	5.2e-05	0.000289	CcSEcCtD
Erlotinib—Dermatitis—Pravastatin—coronary artery disease	5.2e-05	0.000289	CcSEcCtD
Erlotinib—Decreased appetite—Ramipril—coronary artery disease	5.19e-05	0.000289	CcSEcCtD
Erlotinib—Asthenia—Furosemide—coronary artery disease	5.18e-05	0.000288	CcSEcCtD
Erlotinib—Headache—Pravastatin—coronary artery disease	5.17e-05	0.000287	CcSEcCtD
Erlotinib—Anorexia—Lisinopril—coronary artery disease	5.17e-05	0.000287	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Ramipril—coronary artery disease	5.16e-05	0.000287	CcSEcCtD
Erlotinib—Fatigue—Ramipril—coronary artery disease	5.15e-05	0.000286	CcSEcCtD
Erlotinib—Dyspepsia—Timolol—coronary artery disease	5.14e-05	0.000286	CcSEcCtD
Erlotinib—Nausea—Valsartan—coronary artery disease	5.12e-05	0.000284	CcSEcCtD
Erlotinib—Pruritus—Furosemide—coronary artery disease	5.11e-05	0.000284	CcSEcCtD
Erlotinib—Constipation—Ramipril—coronary artery disease	5.11e-05	0.000284	CcSEcCtD
Erlotinib—Nausea—Olmesartan—coronary artery disease	5.09e-05	0.000283	CcSEcCtD
Erlotinib—Vomiting—Trandolapril—coronary artery disease	5.09e-05	0.000283	CcSEcCtD
Erlotinib—Diarrhoea—Perindopril—coronary artery disease	5.08e-05	0.000283	CcSEcCtD
Erlotinib—Decreased appetite—Timolol—coronary artery disease	5.08e-05	0.000282	CcSEcCtD
Erlotinib—Vomiting—Enalapril—coronary artery disease	5.07e-05	0.000282	CcSEcCtD
Erlotinib—Dizziness—Captopril—coronary artery disease	5.06e-05	0.000281	CcSEcCtD
Erlotinib—Rash—Trandolapril—coronary artery disease	5.05e-05	0.000281	CcSEcCtD
Erlotinib—Dermatitis—Trandolapril—coronary artery disease	5.05e-05	0.00028	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Timolol—coronary artery disease	5.04e-05	0.00028	CcSEcCtD
Erlotinib—Fatigue—Timolol—coronary artery disease	5.04e-05	0.00028	CcSEcCtD
Erlotinib—Rash—Enalapril—coronary artery disease	5.03e-05	0.00028	CcSEcCtD
Erlotinib—Dermatitis—Enalapril—coronary artery disease	5.03e-05	0.000279	CcSEcCtD
Erlotinib—Headache—Trandolapril—coronary artery disease	5.02e-05	0.000279	CcSEcCtD
Erlotinib—Vomiting—Telmisartan—coronary artery disease	5e-05	0.000278	CcSEcCtD
Erlotinib—Asthenia—Losartan—coronary artery disease	5e-05	0.000278	CcSEcCtD
Erlotinib—Headache—Enalapril—coronary artery disease	5e-05	0.000278	CcSEcCtD
Erlotinib—Pain—Timolol—coronary artery disease	5e-05	0.000278	CcSEcCtD
Erlotinib—Nausea—Niacin—coronary artery disease	4.98e-05	0.000277	CcSEcCtD
Erlotinib—Rash—Telmisartan—coronary artery disease	4.96e-05	0.000276	CcSEcCtD
Erlotinib—Dermatitis—Telmisartan—coronary artery disease	4.96e-05	0.000276	CcSEcCtD
Erlotinib—Diarrhoea—Furosemide—coronary artery disease	4.94e-05	0.000275	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Lisinopril—coronary artery disease	4.94e-05	0.000274	CcSEcCtD
Erlotinib—Pruritus—Losartan—coronary artery disease	4.93e-05	0.000274	CcSEcCtD
Erlotinib—Headache—Telmisartan—coronary artery disease	4.93e-05	0.000274	CcSEcCtD
Erlotinib—Dizziness—Perindopril—coronary artery disease	4.91e-05	0.000273	CcSEcCtD
Erlotinib—Insomnia—Lisinopril—coronary artery disease	4.9e-05	0.000272	CcSEcCtD
Erlotinib—Nausea—Pravastatin—coronary artery disease	4.9e-05	0.000272	CcSEcCtD
Erlotinib—Gastrointestinal pain—Ramipril—coronary artery disease	4.89e-05	0.000272	CcSEcCtD
Erlotinib—Vomiting—Captopril—coronary artery disease	4.87e-05	0.00027	CcSEcCtD
Erlotinib—Dyspnoea—Lisinopril—coronary artery disease	4.83e-05	0.000269	CcSEcCtD
Erlotinib—Rash—Captopril—coronary artery disease	4.82e-05	0.000268	CcSEcCtD
Erlotinib—Dermatitis—Captopril—coronary artery disease	4.82e-05	0.000268	CcSEcCtD
Erlotinib—Headache—Captopril—coronary artery disease	4.79e-05	0.000266	CcSEcCtD
Erlotinib—Gastrointestinal pain—Timolol—coronary artery disease	4.78e-05	0.000266	CcSEcCtD
Erlotinib—Dizziness—Furosemide—coronary artery disease	4.78e-05	0.000265	CcSEcCtD
Erlotinib—Dyspepsia—Lisinopril—coronary artery disease	4.77e-05	0.000265	CcSEcCtD
Erlotinib—Diarrhoea—Losartan—coronary artery disease	4.77e-05	0.000265	CcSEcCtD
Erlotinib—Nausea—Trandolapril—coronary artery disease	4.76e-05	0.000264	CcSEcCtD
Erlotinib—Nausea—Enalapril—coronary artery disease	4.74e-05	0.000263	CcSEcCtD
Erlotinib—Vomiting—Perindopril—coronary artery disease	4.72e-05	0.000263	CcSEcCtD
Erlotinib—Abdominal pain—Ramipril—coronary artery disease	4.72e-05	0.000263	CcSEcCtD
Erlotinib—Body temperature increased—Ramipril—coronary artery disease	4.72e-05	0.000263	CcSEcCtD
Erlotinib—Decreased appetite—Lisinopril—coronary artery disease	4.71e-05	0.000262	CcSEcCtD
Erlotinib—Rash—Perindopril—coronary artery disease	4.68e-05	0.00026	CcSEcCtD
Erlotinib—Dermatitis—Perindopril—coronary artery disease	4.68e-05	0.00026	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Lisinopril—coronary artery disease	4.68e-05	0.00026	CcSEcCtD
Erlotinib—Nausea—Telmisartan—coronary artery disease	4.67e-05	0.00026	CcSEcCtD
Erlotinib—Fatigue—Lisinopril—coronary artery disease	4.67e-05	0.00026	CcSEcCtD
Erlotinib—Headache—Perindopril—coronary artery disease	4.65e-05	0.000259	CcSEcCtD
Erlotinib—Pain—Lisinopril—coronary artery disease	4.63e-05	0.000258	CcSEcCtD
Erlotinib—Constipation—Lisinopril—coronary artery disease	4.63e-05	0.000258	CcSEcCtD
Erlotinib—Abdominal pain—Timolol—coronary artery disease	4.62e-05	0.000257	CcSEcCtD
Erlotinib—Body temperature increased—Timolol—coronary artery disease	4.62e-05	0.000257	CcSEcCtD
Erlotinib—Dizziness—Losartan—coronary artery disease	4.61e-05	0.000256	CcSEcCtD
Erlotinib—Vomiting—Furosemide—coronary artery disease	4.59e-05	0.000255	CcSEcCtD
Erlotinib—Rash—Furosemide—coronary artery disease	4.55e-05	0.000253	CcSEcCtD
Erlotinib—Dermatitis—Furosemide—coronary artery disease	4.55e-05	0.000253	CcSEcCtD
Erlotinib—Nausea—Captopril—coronary artery disease	4.55e-05	0.000253	CcSEcCtD
Erlotinib—Headache—Furosemide—coronary artery disease	4.52e-05	0.000252	CcSEcCtD
Erlotinib—Gastrointestinal pain—Lisinopril—coronary artery disease	4.43e-05	0.000246	CcSEcCtD
Erlotinib—Vomiting—Losartan—coronary artery disease	4.43e-05	0.000246	CcSEcCtD
Erlotinib—Nausea—Perindopril—coronary artery disease	4.41e-05	0.000245	CcSEcCtD
Erlotinib—Rash—Losartan—coronary artery disease	4.39e-05	0.000244	CcSEcCtD
Erlotinib—Dermatitis—Losartan—coronary artery disease	4.39e-05	0.000244	CcSEcCtD
Erlotinib—Headache—Losartan—coronary artery disease	4.37e-05	0.000243	CcSEcCtD
Erlotinib—Nausea—Furosemide—coronary artery disease	4.29e-05	0.000238	CcSEcCtD
Erlotinib—Asthenia—Ramipril—coronary artery disease	4.29e-05	0.000238	CcSEcCtD
Erlotinib—Abdominal pain—Lisinopril—coronary artery disease	4.28e-05	0.000238	CcSEcCtD
Erlotinib—Body temperature increased—Lisinopril—coronary artery disease	4.28e-05	0.000238	CcSEcCtD
Erlotinib—Pruritus—Ramipril—coronary artery disease	4.23e-05	0.000235	CcSEcCtD
Erlotinib—Asthenia—Timolol—coronary artery disease	4.19e-05	0.000233	CcSEcCtD
Erlotinib—Nausea—Losartan—coronary artery disease	4.14e-05	0.00023	CcSEcCtD
Erlotinib—Pruritus—Timolol—coronary artery disease	4.13e-05	0.00023	CcSEcCtD
Erlotinib—Diarrhoea—Ramipril—coronary artery disease	4.09e-05	0.000227	CcSEcCtD
Erlotinib—Diarrhoea—Timolol—coronary artery disease	4e-05	0.000222	CcSEcCtD
Erlotinib—Dizziness—Ramipril—coronary artery disease	3.95e-05	0.00022	CcSEcCtD
Erlotinib—Asthenia—Lisinopril—coronary artery disease	3.89e-05	0.000216	CcSEcCtD
Erlotinib—Dizziness—Timolol—coronary artery disease	3.86e-05	0.000215	CcSEcCtD
Erlotinib—Pruritus—Lisinopril—coronary artery disease	3.83e-05	0.000213	CcSEcCtD
Erlotinib—Vomiting—Ramipril—coronary artery disease	3.8e-05	0.000211	CcSEcCtD
Erlotinib—Rash—Ramipril—coronary artery disease	3.77e-05	0.000209	CcSEcCtD
Erlotinib—Dermatitis—Ramipril—coronary artery disease	3.76e-05	0.000209	CcSEcCtD
Erlotinib—Headache—Ramipril—coronary artery disease	3.74e-05	0.000208	CcSEcCtD
Erlotinib—Vomiting—Timolol—coronary artery disease	3.71e-05	0.000206	CcSEcCtD
Erlotinib—Diarrhoea—Lisinopril—coronary artery disease	3.71e-05	0.000206	CcSEcCtD
Erlotinib—Rash—Timolol—coronary artery disease	3.68e-05	0.000205	CcSEcCtD
Erlotinib—Dermatitis—Timolol—coronary artery disease	3.68e-05	0.000205	CcSEcCtD
Erlotinib—Headache—Timolol—coronary artery disease	3.66e-05	0.000203	CcSEcCtD
Erlotinib—Dizziness—Lisinopril—coronary artery disease	3.58e-05	0.000199	CcSEcCtD
Erlotinib—Nausea—Ramipril—coronary artery disease	3.55e-05	0.000197	CcSEcCtD
Erlotinib—Nausea—Timolol—coronary artery disease	3.47e-05	0.000193	CcSEcCtD
Erlotinib—Vomiting—Lisinopril—coronary artery disease	3.45e-05	0.000192	CcSEcCtD
Erlotinib—Rash—Lisinopril—coronary artery disease	3.42e-05	0.00019	CcSEcCtD
Erlotinib—Dermatitis—Lisinopril—coronary artery disease	3.41e-05	0.00019	CcSEcCtD
Erlotinib—Headache—Lisinopril—coronary artery disease	3.39e-05	0.000189	CcSEcCtD
Erlotinib—Nausea—Lisinopril—coronary artery disease	3.22e-05	0.000179	CcSEcCtD
Erlotinib—CYP2D6—Metabolism—PLCB1—coronary artery disease	1.45e-06	1.06e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAT—coronary artery disease	1.45e-06	1.06e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GOT1—coronary artery disease	1.44e-06	1.06e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GGT1—coronary artery disease	1.44e-06	1.06e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAT—coronary artery disease	1.44e-06	1.05e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLCB3—coronary artery disease	1.44e-06	1.05e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GPX1—coronary artery disease	1.43e-06	1.05e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK1—coronary artery disease	1.43e-06	1.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—coronary artery disease	1.43e-06	1.04e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOA5—coronary artery disease	1.43e-06	1.04e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—coronary artery disease	1.42e-06	1.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GSK3B—coronary artery disease	1.41e-06	1.03e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOB—coronary artery disease	1.41e-06	1.03e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCA1—coronary artery disease	1.41e-06	1.03e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOB—coronary artery disease	1.4e-06	1.02e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—P4HB—coronary artery disease	1.4e-06	1.02e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—coronary artery disease	1.4e-06	1.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—POMC—coronary artery disease	1.4e-06	1.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CREB1—coronary artery disease	1.4e-06	1.02e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CD36—coronary artery disease	1.39e-06	1.02e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—coronary artery disease	1.39e-06	1.01e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PSMB5—coronary artery disease	1.38e-06	1.01e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PSMA6—coronary artery disease	1.38e-06	1.01e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	1.38e-06	1.01e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPP2CA—coronary artery disease	1.37e-06	1.01e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLA2G1B—coronary artery disease	1.37e-06	1e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—coronary artery disease	1.37e-06	1e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—coronary artery disease	1.37e-06	1e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—coronary artery disease	1.37e-06	1e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL2—coronary artery disease	1.37e-06	1e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6R—coronary artery disease	1.36e-06	9.96e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GGT1—coronary artery disease	1.36e-06	9.96e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GOT1—coronary artery disease	1.36e-06	9.96e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—coronary artery disease	1.36e-06	9.96e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NOS3—coronary artery disease	1.36e-06	9.95e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CTGF—coronary artery disease	1.35e-06	9.86e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—LPL—coronary artery disease	1.34e-06	9.83e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1—coronary artery disease	1.34e-06	9.83e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK1—coronary artery disease	1.34e-06	9.82e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK1—coronary artery disease	1.34e-06	9.78e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMGCR—coronary artery disease	1.34e-06	9.77e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GOT2—coronary artery disease	1.34e-06	9.77e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—LPL—coronary artery disease	1.34e-06	9.77e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AGT—coronary artery disease	1.33e-06	9.71e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—coronary artery disease	1.32e-06	9.65e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GPX1—coronary artery disease	1.31e-06	9.59e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GPX1—coronary artery disease	1.3e-06	9.54e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOE—coronary artery disease	1.3e-06	9.51e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—coronary artery disease	1.3e-06	9.49e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—VCAN—coronary artery disease	1.29e-06	9.47e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARGC1A—coronary artery disease	1.29e-06	9.41e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOA1—coronary artery disease	1.29e-06	9.4e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALDOA—coronary artery disease	1.28e-06	9.39e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HMOX1—coronary artery disease	1.28e-06	9.36e-06	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—coronary artery disease	1.28e-06	9.36e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—coronary artery disease	1.28e-06	9.34e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CD36—coronary artery disease	1.28e-06	9.34e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SERPINE1—coronary artery disease	1.28e-06	9.33e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CD36—coronary artery disease	1.27e-06	9.29e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAT—coronary artery disease	1.26e-06	9.24e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPP2CA—coronary artery disease	1.26e-06	9.22e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AGT—coronary artery disease	1.25e-06	9.17e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPP2CA—coronary artery disease	1.25e-06	9.17e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DCN—coronary artery disease	1.25e-06	9.12e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—coronary artery disease	1.24e-06	9.1e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—coronary artery disease	1.24e-06	9.07e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF2—coronary artery disease	1.23e-06	9.03e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PLCB1—coronary artery disease	1.23e-06	8.99e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOE—coronary artery disease	1.23e-06	8.99e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOB—coronary artery disease	1.23e-06	8.97e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—coronary artery disease	1.22e-06	8.95e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK1—coronary artery disease	1.22e-06	8.94e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOS3—coronary artery disease	1.22e-06	8.91e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOA1—coronary artery disease	1.21e-06	8.88e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALDH2—coronary artery disease	1.21e-06	8.87e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	1.21e-06	8.86e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—coronary artery disease	1.21e-06	8.85e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HMOX1—coronary artery disease	1.21e-06	8.82e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	1.2e-06	8.82e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—coronary artery disease	1.2e-06	8.8e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—coronary artery disease	1.19e-06	8.72e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCA1—coronary artery disease	1.19e-06	8.71e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAT—coronary artery disease	1.19e-06	8.71e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JAK2—coronary artery disease	1.18e-06	8.66e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HBA1—coronary artery disease	1.18e-06	8.65e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—LIPC—coronary artery disease	1.18e-06	8.65e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2C19—coronary artery disease	1.18e-06	8.65e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	1.18e-06	8.65e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOC3—coronary artery disease	1.17e-06	8.59e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—LPL—coronary artery disease	1.17e-06	8.56e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—LDLR—coronary artery disease	1.17e-06	8.54e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—coronary artery disease	1.16e-06	8.52e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.16e-06	8.51e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—coronary artery disease	1.16e-06	8.49e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOB—coronary artery disease	1.15e-06	8.45e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	1.15e-06	8.44e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—coronary artery disease	1.15e-06	8.44e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GOT1—coronary artery disease	1.15e-06	8.44e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GGT1—coronary artery disease	1.15e-06	8.44e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—coronary artery disease	1.15e-06	8.41e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AGT—coronary artery disease	1.15e-06	8.41e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AGT—coronary artery disease	1.14e-06	8.36e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPX1—coronary artery disease	1.14e-06	8.35e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GCLC—coronary artery disease	1.14e-06	8.34e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CETP—coronary artery disease	1.14e-06	8.34e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—coronary artery disease	1.13e-06	8.29e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—coronary artery disease	1.13e-06	8.27e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK1—coronary artery disease	1.13e-06	8.25e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SDC1—coronary artery disease	1.13e-06	8.25e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOE—coronary artery disease	1.13e-06	8.24e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—coronary artery disease	1.12e-06	8.22e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOE—coronary artery disease	1.12e-06	8.19e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—POMC—coronary artery disease	1.12e-06	8.17e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOA1—coronary artery disease	1.11e-06	8.14e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CD36—coronary artery disease	1.11e-06	8.14e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOA1—coronary artery disease	1.11e-06	8.1e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—LPL—coronary artery disease	1.1e-06	8.07e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPP2CA—coronary artery disease	1.1e-06	8.03e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—coronary artery disease	1.1e-06	8.03e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—coronary artery disease	1.08e-06	7.9e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPX1—coronary artery disease	1.08e-06	7.87e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—coronary artery disease	1.07e-06	7.83e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.07e-06	7.8e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PSMA6—coronary artery disease	1.06e-06	7.79e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PSMB5—coronary artery disease	1.06e-06	7.79e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.06e-06	7.75e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—coronary artery disease	1.06e-06	7.75e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—POMC—coronary artery disease	1.06e-06	7.72e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—coronary artery disease	1.05e-06	7.71e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CD36—coronary artery disease	1.05e-06	7.67e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—coronary artery disease	1.04e-06	7.63e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CTGF—coronary artery disease	1.04e-06	7.61e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—coronary artery disease	1.04e-06	7.58e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPP2CA—coronary artery disease	1.03e-06	7.57e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—coronary artery disease	1.03e-06	7.56e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMGCR—coronary artery disease	1.03e-06	7.54e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GOT2—coronary artery disease	1.03e-06	7.54e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—coronary artery disease	1.03e-06	7.51e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARGC1A—coronary artery disease	1.03e-06	7.51e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMOX1—coronary artery disease	1.02e-06	7.47e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—coronary artery disease	1.02e-06	7.45e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—coronary artery disease	1.01e-06	7.41e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAT—coronary artery disease	1.01e-06	7.37e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—coronary artery disease	1.01e-06	7.36e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AGT—coronary artery disease	1e-06	7.33e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—coronary artery disease	9.93e-07	7.27e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOE—coronary artery disease	9.81e-07	7.18e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—coronary artery disease	9.81e-07	7.18e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOB—coronary artery disease	9.78e-07	7.16e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—coronary artery disease	9.78e-07	7.16e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—coronary artery disease	9.77e-07	7.15e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—coronary artery disease	9.75e-07	7.14e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NOS3—coronary artery disease	9.74e-07	7.13e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOA1—coronary artery disease	9.7e-07	7.1e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—POMC—coronary artery disease	9.67e-07	7.08e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—coronary artery disease	9.62e-07	7.04e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—POMC—coronary artery disease	9.62e-07	7.04e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—coronary artery disease	9.52e-07	6.96e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—coronary artery disease	9.51e-07	6.96e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLCB1—coronary artery disease	9.48e-07	6.94e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—coronary artery disease	9.47e-07	6.93e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AGT—coronary artery disease	9.43e-07	6.9e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—coronary artery disease	9.38e-07	6.87e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—LPL—coronary artery disease	9.34e-07	6.84e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOE—coronary artery disease	9.24e-07	6.76e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NOS3—coronary artery disease	9.2e-07	6.73e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCA1—coronary artery disease	9.19e-07	6.72e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOA1—coronary artery disease	9.14e-07	6.69e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPX1—coronary artery disease	9.11e-07	6.67e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—coronary artery disease	9.01e-07	6.6e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—coronary artery disease	8.91e-07	6.52e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GOT1—coronary artery disease	8.9e-07	6.51e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GGT1—coronary artery disease	8.9e-07	6.51e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CD36—coronary artery disease	8.88e-07	6.5e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—coronary artery disease	8.82e-07	6.45e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—coronary artery disease	8.77e-07	6.42e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPP2CA—coronary artery disease	8.77e-07	6.41e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—coronary artery disease	8.66e-07	6.34e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—coronary artery disease	8.66e-07	6.33e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—coronary artery disease	8.54e-07	6.25e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NOS3—coronary artery disease	8.44e-07	6.17e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—POMC—coronary artery disease	8.43e-07	6.17e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—coronary artery disease	8.42e-07	6.16e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—coronary artery disease	8.41e-07	6.16e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—coronary artery disease	8.41e-07	6.15e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NOS3—coronary artery disease	8.39e-07	6.14e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—coronary artery disease	8.05e-07	5.89e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—coronary artery disease	8.05e-07	5.89e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—coronary artery disease	7.99e-07	5.85e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AGT—coronary artery disease	7.99e-07	5.85e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—coronary artery disease	7.99e-07	5.85e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—POMC—coronary artery disease	7.94e-07	5.81e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	7.92e-07	5.79e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK1—coronary artery disease	7.9e-07	5.78e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMOX1—coronary artery disease	7.88e-07	5.77e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOE—coronary artery disease	7.83e-07	5.73e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAT—coronary artery disease	7.78e-07	5.69e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOA1—coronary artery disease	7.74e-07	5.66e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—coronary artery disease	7.72e-07	5.65e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—coronary artery disease	7.68e-07	5.62e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—coronary artery disease	7.67e-07	5.61e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—coronary artery disease	7.65e-07	5.6e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOB—coronary artery disease	7.55e-07	5.53e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	7.41e-07	5.42e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—coronary artery disease	7.36e-07	5.39e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NOS3—coronary artery disease	7.35e-07	5.38e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—coronary artery disease	7.35e-07	5.37e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—coronary artery disease	7.24e-07	5.3e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—LPL—coronary artery disease	7.21e-07	5.28e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPX1—coronary artery disease	7.03e-07	5.15e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NOS3—coronary artery disease	6.93e-07	5.07e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—coronary artery disease	6.87e-07	5.03e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CD36—coronary artery disease	6.85e-07	5.01e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—coronary artery disease	6.85e-07	5.01e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—coronary artery disease	6.82e-07	4.99e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	6.77e-07	4.95e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—POMC—coronary artery disease	6.73e-07	4.92e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—coronary artery disease	6.72e-07	4.92e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—coronary artery disease	6.49e-07	4.75e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—coronary artery disease	6.33e-07	4.63e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—coronary artery disease	6.25e-07	4.57e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AGT—coronary artery disease	6.17e-07	4.51e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—coronary artery disease	6.13e-07	4.49e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—coronary artery disease	6.07e-07	4.44e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOE—coronary artery disease	6.04e-07	4.42e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOA1—coronary artery disease	5.97e-07	4.37e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NOS3—coronary artery disease	5.87e-07	4.29e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—coronary artery disease	5.6e-07	4.1e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—coronary artery disease	5.48e-07	4.01e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—coronary artery disease	5.37e-07	3.93e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—coronary artery disease	5.26e-07	3.85e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—POMC—coronary artery disease	5.19e-07	3.8e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—coronary artery disease	5.18e-07	3.79e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—coronary artery disease	4.75e-07	3.47e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—coronary artery disease	4.73e-07	3.46e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—coronary artery disease	4.72e-07	3.45e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NOS3—coronary artery disease	4.53e-07	3.31e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—coronary artery disease	4.48e-07	3.28e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—coronary artery disease	4.23e-07	3.09e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—coronary artery disease	4.14e-07	3.03e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—coronary artery disease	4.14e-07	3.03e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—coronary artery disease	3.9e-07	2.85e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—coronary artery disease	3.88e-07	2.84e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—coronary artery disease	3.86e-07	2.82e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—coronary artery disease	3.38e-07	2.47e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—coronary artery disease	3.3e-07	2.42e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—coronary artery disease	3.18e-07	2.33e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—coronary artery disease	2.7e-07	1.97e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	2.55e-07	1.86e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—coronary artery disease	2.08e-07	1.52e-06	CbGpPWpGaD
